<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0037">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Pillaiyar</surname>
    <given-names>T.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Manickam</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Namasivayam</surname>
    <given-names>V.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hayashi</surname>
    <given-names>Y.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Jung</surname>
    <given-names>S. H.</given-names>
   </name>
  </person-group> (
  <year>2016</year>). 
  <article-title>An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy</article-title>. 
  <source>
   <italic>Journal of Medicinal Chemistry</italic>
  </source>, 
  <volume>59</volume>(
  <issue>14</issue>), 
  <fpage>6595</fpage>â€“
  <lpage>6628</lpage>. 
  <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01461</pub-id>
  <pub-id pub-id-type="pmid">26878082</pub-id>
 </mixed-citation>
</ref>
